

1 Programmatic considerations for chikungunya vaccine 2 introduction in countries at risk of chikungunya outbreaks: 3 stakeholder analysis

4
5 Megan Auzenbergs¹, Clara Maure², Hyolim Kang¹, Oliver Brady¹, Sushant Sahastrabudhe^{2*}, Kaja
6 Abbas^{1,3*}

7
8 ¹London School of Hygiene and Tropical Medicine, London, UK

9 ²International Vaccine Institute, Seoul, South Korea

10 ³School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan

11
12 *Contributed equally

13 Correspondence: megan.auzenbergs@lshtm.ac.uk

14 Abstract

15 Chikungunya can have longstanding effects on health and quality of life. Alongside the licensing of
16 new chikungunya vaccines in the pipeline, it is important to understand the perspectives of
17 stakeholders before vaccine rollout. Our study aim is to identify key programmatic considerations for
18 chikungunya vaccine introduction in countries at risk of chikungunya outbreaks. We used purposive
19 and snowball sampling to identify global, national, and subnational stakeholders from outbreak
20 prone areas, including Latin America, Asia, and Africa. Semi-structured in-depth interviews were
21 conducted and analysed using qualitative descriptive methods. We found that perspectives varied
22 between tiers of stakeholders and geographies. Unknown disease burden, diagnostics, non-specific
23 disease surveillance, undefined target populations for vaccination, and low disease prioritisation
24 were critical challenges identified by stakeholders that need to be addressed to facilitate rolling out a
25 chikungunya vaccine. Future investments should address these challenges to generate useful
26 evidence for decision-making on new chikungunya vaccine introduction.
27

28 Introduction

29 Chikungunya is a mosquito-borne neglected tropical disease (NTD) caused by the chikungunya virus
30 (CHIKV), an alphavirus spread by the mosquito vectors *Aedes aegypti* and *Aedes albopictus*.
31 Symptoms associated with chikungunya fever are often mild, but can be associated with severe
32 morbidities, such as persistent arthralgia, reported in 88% of cases up to one month after infection
33 [1] and severe chronic arthralgia lasting years after infection [2, 3]. The severe, chronic morbidities
34 associated with chikungunya fever can have longstanding effects on health and quality of life.
35

36 The stochastic transmission dynamics of CHIKV make it difficult to predict when the next outbreak
37 will occur or if CHIKV will become endemic in any specific setting. Chikungunya cases have
38 historically been clustered in tropical areas with warm, humid climates where the vectors thrive and
39 cause recurring outbreaks of chikungunya fever. However, the increasing spread of the vector to
40 more geographic regions due to climate change poses a greater risk of CHIKV to more people in the
41 future [4, 5]. CHIKV-carrying mosquitoes are currently endemic in the Americas, parts of Africa, and
42 Southeast Asia [6]. These geographical regions are at high-risk of infection and carry the greatest
43 burden of global chikungunya cases.
44

45 There is no current vaccine to prevent chikungunya infection, but several promising vaccine
46 candidates are in clinical trials. The most advanced vaccine candidate, manufactured by Valneva,
47 recently demonstrated sustained high-titre neutralising antibodies and high rates of seroconversion
48 following a single-dose of vaccine alongside a successful safety analysis [7]. This vaccine's license

49 application was successfully approved by the Food and Drug Administration (FDA) for priority review
50 in February 2023 [8]. Additionally, the chikungunya vaccine is being considered in the Global Alliance
51 for Vaccines and Immunisation (GAVI) Vaccine Investment Strategy [9] for stockpiling and outbreak
52 response alongside continued investment from The Coalition for Epidemic Preparedness
53 Innovations (CEPI). CEPI's strategic concerns for this vaccine span both the vaccine development
54 processes and ensuring equitable access to vaccines for chikungunya endemic countries [10]. A
55 schematic showing the timeline and evolution of the chikungunya vaccine is presented in Figure 1.

56

57 **Figure 1. Chikungunya vaccine development to introduction pathway.** Schematic
58 showing the vaccine development process for the chikungunya vaccine alongside
59 stages of licensure and evidence-based recommendations for policy making
60 decisions. WHO – World Health Organization; MoH – Ministry of Health, NRA - National
61 Regulatory Agencies, SAGE – Strategic Advisory Group of Experts, EPI – Expanded Program for
62 Immunization, NITAG – National Immunization Technical Advisory Group, PQ- Pre-qualification
63

64

64 A chikungunya vaccine provides primary value in reducing global burden of CHIKV and long-term side
65 effects associated with CHIKV infection. It also provides additional significant value since this is also
66 the first vaccine against an alphavirus genus in the *Togaviridae* family, thereby enabling a novel
67 vaccine development platform against emerging alphaviruses in the *Togaviridae* family [11]. As the
68 risk of emerging infections increases with global travel and climate change, having an existing
69 mechanism for developing a vaccine against an emerging pathogen expedites global outbreak
70 response and vaccine development, as was done with mRNA and viral-vector vaccines during the
71 COVID-19 pandemic [12].

72

73 Evidence to recommend chikungunya vaccine introduction is needed, including the disease burden,
74 benefits and harms of chikungunya vaccination, values and preferences of the target population,
75 acceptability to stakeholders, resources use and economic impact, equity, and feasibility [13]. As the
76 global risk of CHIKV infection increases alongside introduction of the first chikungunya vaccine, we
77 urgently need to understand the target populations for the new vaccine in addition to context
78 specific social, logistical and financial barriers to rolling out the vaccine [14]. To date, qualitative
79 research on chikungunya has been limited to patient experience, specifically quality of life and
80 coping strategies following infection [15]. Further, there is a lack of research exploring cultural
81 explanations and conceptualizations of CHIKV aetiology in different geographical areas [16].

82

83 A gap in knowledge persists in stakeholder perceptions of both the risk of chikungunya outbreaks
84 and perspectives around the feasibility of chikungunya vaccination. To our knowledge, this is the first
85 study to synthesise stakeholder perceptions on chikungunya outbreaks and vaccination by
86 interviewing a diverse sample of global, national and subnational stakeholders involved in different
87 elements of chikungunya epidemiology, policy, outbreak control and vaccinology. We aim to provide
88 timely implications for decision-making alongside qualitative data from a robust sample of
89 stakeholders to inform introduction of the first available and licensed chikungunya vaccine.

90 Methods

91 Stakeholder selection

92 We conducted a scoping review on chikungunya epidemiology to identify geographical regions at risk
93 of chikungunya outbreaks alongside countries with ongoing clinical trials of chikungunya vaccine
94 candidates. The regions of Latin America, Africa and Asia were prioritised for stakeholder
95 identification. From here, a diverse list of contacts was created using purposive and snowball
96 sampling of organisational databases, search engines and input from project coordinators at the
97 International Vaccine Institute who oversee several clinical trial networks for chikungunya. At the end

98 of all interviews, we requested stakeholders to recommend colleagues that would be also interested
99 in taking part in an interview, to which a follow-up invite was sent.

100

101 Participants were first grouped into geographical categories and then grouped into one of three
102 hierarchical categories: global, national or subnational stakeholders, referred to later as stakeholder
103 tiers. From all geographical regions sampled, global stakeholders included experts from international
104 organisations focused on immunisation and academics with a focus on arbovirus research in one of
105 the aforementioned high-burden regions. National stakeholders included experts working at country-
106 level ministries of health or within a policy sector for vaccine regulatory approval and oversight.
107 Subnational stakeholders included clinicians, laboratory scientists and community health workers
108 with experience working with chikungunya patients or in high-burden areas. Participants were
109 geographically representative of chikungunya burden and evenly split across stakeholder tiers.

110

111 Data collection

112 We developed a semi-structure interview questionnaire (see Appendix Table 1) through
113 consultations with experts in vaccine epidemiology and reviewed existing studies evaluating the
114 perception of stakeholders on other vaccine introductions and rollouts. Questions were focussed on
115 perception of chikungunya outbreak risk, barriers to chikungunya vaccination, and pathways to
116 advance the chikungunya vaccine agenda in the future. At the time of the interviews, there was no
117 licensed chikungunya vaccine, although several vaccine candidates have ongoing or completed phase
118 III clinical trials. As interviews were conducted, questions were revised to reflect new topics that
119 emerged. Biweekly meetings with the research team occurred to ensure the interviews were going
120 smoothly and new themes that emerged through data collection were discussed.

121

122 Data analysis

123 We conducted qualitative semi-structured interviews via video call during which detailed notes were
124 transcribed. We analysed the interview data through an iterative process using MAXQDA 2022
125 (VERBI Software, 2021) for data analysis and codebook development was done following the
126 methods discussed in MacQueen et al. [17]. We use inductive and deductive coding to analyse the
127 raw interview data. We categorised the coded data into themes. Thematic differences between
128 geographical regions were first identified and then stakeholder tiers were analysed.

129

130 Identification of evidence gaps

131 Guidance on the Evidence to Recommendation process (EtR) used by national immunization
132 technical advisory groups (NITAGs) [13] was used to identify evidence gaps in current chikungunya
133 knowledge and research, as shown in Figure 2. EtR criteria were then aligned with stakeholder
134 perspectives and grouped by geographical region to highlight regional evidence gaps.

135

136 Ethics approval

137 Ethical approval for this project was received from the London School of Hygiene and Tropical
138 Medicine in January 2023, project reference number 28292.

139

140 **Figure 2. Evidence to Recommendation criteria for chikungunya vaccine**
141 **introduction.** *The Evidence to Recommendation criteria for chikungunya vaccine*
142 *introduction is based on the World Health Organization's Guidance on an adapted*
143 *Evidence to Recommendation Process for National Immunization Technical*
144 *Advisory Groups.*

145 **Results**

146 **Participant characteristics**

147 Between January-February 2023, approximately 60 stakeholders were emailed and invited to take
148 part in an interview. Overall, a total of 18 stakeholder interviews were conducted via video call
149 between February and July 2023 (see Table 1).

150

151 **Table 1. Participant characteristics by geographical region and type of stakeholder**

Geographical region	Country	Type of stakeholder	Number of interviewees
Latin America	Brazil	National	3
		Subnational	1
	Guatemala	Subnational	1
	Colombia	National	2
		Subnational	2
Asia	Thailand	National	2
	India	National	1
		Subnational	1
Africa	Kenya	Subnational	2
International		Global	3
Total			18

152

153 **Implications for decision making**

154 We identified several themes for challenges associated with chikungunya vaccine introduction.
155 Notable differences exist within stakeholder in different organisation tiers and by geographical
156 regions (see Table 2).

Table 2. Themes and challenges presented by stakeholders in different organisation tiers and by geographical regions

Theme	Challenges presented by stakeholders in different organisation tiers			Challenges presented by stakeholders in different geographical regions			
	Subnational level	National level	Global level	Latin America	Asia	Africa	International
Unknown burden of disease	A lack of diagnostic sensitivity and laboratory capacity in the most affected areas results in an under diagnosis and under reporting of CHIKV	Surveillance for CHIKV is lacking in areas, which makes it difficult to understand which areas are most affected, detect outbreaks and respond accordingly	Without a good understanding of disease burden, demonstrating the economic burden of chikungunya or economic impact of a vaccine is challenging	Non-specific disease surveillance makes it difficult to distinguish the burden of disease between CHIKV, dengue and zika	Unknown CHIKV burden makes it difficult to advocate for CHIKV prevention and vaccination over dengue	Inability to detect actual CHIKV cases amongst other febrile illnesses, such as malaria, results in a large under-estimation in disease burden	Prioritisation of the vaccine in certain geographical regions is uncertain, making investment case for the vaccine difficult
Chikungunya has a high burden of morbidity, but not mortality making disease prioritisation uncertain	Public perception around chikungunya can be lacking in areas with endemic dengue circulating	It is difficult to prioritise chikungunya over other pathogens (specifically dengue or zika) when it comes to investing in developing improved laboratory and surveillance methods	Country buy-in is important for future vaccine investment strategies	Despite co-circulation of CHIKV with other arboviruses and lower mortality rates, the chikungunya vaccine is a priority and countries are preparing for vaccine rollout	Lack of buy in from national vaccine policymakers to prioritise the chikungunya vaccine over the dengue vaccine	Prioritisation of other diseases with higher mortality rates means chikungunya is rarely discussed, and public awareness about the disease is lacking	Varying levels of prioritisation and support for the vaccine makes it difficult to plan for vaccine introduction
Target population for the chikungunya vaccine is not well defined	Vaccine confidence and public perception of a chikungunya vaccine would affect the success of a vaccine roll-out	Ensuring that the right infrastructure is in place to deliver the vaccine is difficult because the exact target population and delivery method	Understanding the exact use of the vaccine and the target populations are important for stockpile estimates, which are part of a global vaccine	Anticipated use in outbreak response and affected areas, but approval of the current vaccine only for use in 18-years and older	Disease burden varies greatly within some countries, so subnational infrastructures would need to be in place to improve	Research shows a high burden amongst children, but lack of age-specific serodata makes it hard to define a target population, the vaccine has also	Following the safety approvals for the vaccine and recommended age groups may make outbreak trajectory uncertain if

		(outbreak response or routine immunisation) is unknown	investment strategy	individuals means uncertainty if/when children can be vaccinated	diagnostics and support vaccination at the local level	not been evaluated in children	outbreak data shows high burden amongst children
Chikungunya has specific climate or vector factors to consider	Different disease burdens are experienced by different sub-populations because of vector exposure	As vector epidemiology changes, CHIKV may become endemic in some countries, this has implications for vaccine stockpiles and roll-out	The technology behind the chikungunya vaccine may aid development of other alphaviruses in the <i>Togaviridae</i> family	Chikungunya and dengue cocirculate and concurrent outbreaks have occurred. It is important to understand how to deploy both the dengue and chikungunya vaccines in outbreak settings	Vector viability can differ within the same country, so sometimes local prevention measures and vaccination would be preferred over national programmes or campaigns	The animal reservoir in Africa demonstrates sylvatic transmission and viral evolution, so global chikungunya prevention should be concerned with natural origins of the virus	As global travel patterns and climate change affect viability of settings for the chikungunya vector, epidemic trends and spatial epidemiology may shift

159 Unknown burden of disease

160 The disease burden of chikungunya is unknown in many settings, which was the most frequently
161 mentioned barrier to uptake of a chikungunya vaccine reiterated by stakeholders across all
162 organisation tiers and geographical regions, alongside awareness of the unpredictability of
163 chikungunya outbreaks.

164

165 Stakeholders partially attribute the unknown burden to non-specific or insensitive surveillance as
166 surveillance for CHIKV is often done alongside other arboviral diseases, such as dengue and zika.
167 Surveillance for CHIKV is also often based on clinical cases, so passive surveillance only, which
168 stakeholders believe results in under-reporting as surveillance systems usually only capture the cases
169 that seek medical attention. Because this type of case detection relies on symptomatic patients
170 reporting to health systems, passive surveillance excludes less severe or asymptomatic infections.

171

172 Without a comprehensive understanding of disease burden, quantifying the economic burden,
173 including direct and indirect costs of acute but also chronic symptoms is difficult. This barrier
174 primarily affected national and global level stakeholders as countries cannot advocate for
175 interventions, such as vaccination, without a cost-effectiveness and risk benefit analysis.

176

177 *“We need to better understand the burden of disease, disability adjusted life years*
178 *(DALYs) lost, the benefits of a vaccine in terms of reducing morbidity and work*
179 *loss.”*

180 *-Programme lead for chikungunya, international organisation*

181

182 *“We don’t have good chikungunya surveillance, and it is usually paired with*
183 *surveillance for dengue and zika. Surveillance can be coupled with dengue and*
184 *zika, but a good surveillance system should look for mild cases of chikungunya,*
185 *not just severe cases that will look for medical attention. A lot of mild*
186 *chikungunya cases are not found or not reported”*

187 *-Paediatric infectious disease specialist, Guatemala*

188

189 Geographical variations in disease burden

190 We observed regional differences in stakeholder perceptions around chikungunya burden. For
191 African countries, other febrile illnesses make fevers associated with chikungunya difficult to
192 accurately detect.

193 *“The burden of disease is not well defined for chikungunya. We do not understand*
194 *the nature of outbreaks and the burden of disease in African nations because it is*
195 *hidden in other febrile illnesses (malaria, etc.).”*

196 *-Programme lead for chikungunya, international organisation*

197

198 In South America, stakeholders attribute unknown burden mostly to passive surveillance and the fact
199 that outbreaks of chikungunya and dengue sometime occur concurrently.

200

201 *“There is lots of under-reporting because current chikungunya surveillance is*
202 *based on clinical cases, passive surveillance only, not active case detection, so we*
203 *are only capturing cases that seek medical help, not community level cases.”*

204 *-Neglected tropical diseases division, national organisation, Brazil*

205

206 In India, the subnational burden of disease is of concern if a chikungunya vaccine were to be rolled
207 out. This is of particular importance given the large population size of India and infrastructure
208 needed to manufacturer enough vaccine doses and deliver these doses to many people.

209

210 *“There are subnational variations in burden within India. It is a question if the*
211 *vaccine would be rolled out as a pan-national vaccine, or if it would be like the*
212 *Japanese Encephalitis vaccine, which is restricted to only a few areas. Burden is*
213 *limited in some parts of India, except for big states, Delhi, Uttar Pradesh.”*
214 *-Infectious disease clinician, India*

215

216 **Diagnosics**

217 Subnational stakeholders identify additional concerns around improving laboratory diagnostics and
218 not overloading laboratory capacity alongside vaccine interventions. At the subnational level,
219 stakeholders expressed concerns on diagnostic sensitivity and capacity since some diagnostic tests
220 are unable to detect CHIKV infections early enough, and that many high-risk areas are not well-
221 equipped with the laboratory equipment required for CHIKV diagnosis and samples therefore are
222 shipped elsewhere [18, 19].

223

224 *“The amazon region of Brazil does not have good laboratory capacity for*
225 *diagnostics, most samples are shipped to Sao Paulo, so most local diagnoses are*
226 *left to clinical diagnoses. Enhanced serological testing for burden estimates would*
227 *not be possible because of the remoteness of the area.”*

228 *-Nurse and laboratory specialist, Amazon region, Brazil*

229

230 *“You need to know both the symptomatic and asymptomatic burden of*
231 *chikungunya - we will need to determine the asymptomatic burden and confirm*
232 *what genotypes are circulating. To do this, we require: good serology kits for IgM*
233 *and IgG, good PCR that will detect the different circulating strains and a well*
234 *working lab team.”*

235 *-Virology laboratory specialist, India*

236

237 **Unpredictable outbreaks**

238 In places where chikungunya is not endemic, outbreaks are unpredictable. The unpredictability of
239 outbreaks affects stockpiling of vaccine as it is difficult to estimate the time, duration and number
240 affected during each outbreak.

241

242 *“CHIK tends to come in waves, but not predictable waves within regions and*
243 *countries, the prioritisation and national public health interest (and therefore*
244 *funding) is low because the waves only come once in a while and are*
245 *unpredictable, so it is difficult to maintain attention to efforts.”*

246 *-Programme lead for chikungunya, international organisation*

247

248 In other regions, policy stakeholders believe chikungunya would have to become an endemic disease
249 for priority to be given to the chikungunya vaccine.

250

251 *“Even if we have an efficacious [CHIKV] vaccine, there are a number of challenges*
252 *for public use. In comparison to dengue, chikungunya would need to be endemic*
253 *in our region [Southeast Asia]. However, from the epidemiology, we see*
254 *chikungunya cases occurring per year are less than dengue.”*

255 *-Vaccine policy & safety, national organisation, Thailand*

256

257 **Prioritisation of chikungunya over other arboviral diseases**

258 Because chikungunya has a high burden of morbidity, but not mortality in many regions, stakeholders
259 admit it is currently not a high-priority disease. Since countries with the greatest burden of

260 chikungunya also have high burdens of other arboviral diseases, specifically dengue, there are often
261 competing priorities. For example, stakeholders in India and Southeast Asia mostly prioritised
262 chikungunya lower than dengue. One stakeholder from Thailand even refused to partake in an
263 interview because he saw the promotion of a chikungunya vaccine to detract from resources being
264 allocated to dengue vaccine roll-out. Despite this perceived competition, stakeholders in Latin and
265 South America overall had the greatest interest in the chikungunya vaccine and were confident in
266 vaccine roll-out despite concurrent dengue outbreaks, albeit with some concerns about public
267 perception of the vaccine due to lack of perceived risk of morbidities associated with chikungunya.

268

269

270

271

272

273

274

275

“Now that the dengue vaccine is about to be licenced globally in the very near future, dengue may be a higher priority in the same countries where chikungunya is also a problem, so dengue will probably be ahead of chikungunya in the priority list. Latin America is the region that has the most interest in chikungunya, the most concern and high prioritisation. Certain sectors in India may be interested, but overall, broadly, prioritisation in India is lower, they will prioritise dengue over chikungunya”

276

-Programme lead for chikungunya, international organisation

277

278

279

280

281

282

283

284

“The size of morbidity and mortality is lower for chikungunya than dengue, moreover, we rarely see a mortality rate from chikungunya that is similar to that of dengue, particularly in children, so severity (DALYs) is less, burden is less than dengue.... The number of cases of chikungunya does not ring a bell and there is a longer duration between outbreaks, which is hard to predict. We [Thailand] have a number of competitive health problems and we have many things on the priority list”.

285

-Vaccine policy & safety, national organisation, Thailand

286

287

288

289

290

291

292

293

294

“There will be challenges rolling out the chikungunya vaccine. On an individual level, people won't see it as an important vaccine because there is a feeling that chikungunya is a mild disease. The perception is that it is not as important as other diseases. People won't be as eager to get the vaccine, which is different from dengue. Lots of people have seen severe dengue, so if you see people in the hospital with dengue, you know it is a severe disease. But with chikungunya, people usually don't go to the hospital and if they do, they usually don't die from chikungunya.”

295

-Paediatric infectious disease specialist, Guatemala

296

297

298

299

300

Stakeholders state that the lack of vaccine evaluation and an underinvestment in chikungunya research in Africa perpetuates vaccine inequity. Whilst some stakeholders in Latin America have a better understanding of how a chikungunya vaccine would be rolled out, other stakeholders in Africa are concerned about the lack of knowledge about the disease in their geographical region.

301

302

303

304

305

306

307

“Chikungunya was discovered in Tanzania, there has never been a vaccine trial anywhere in Africa, there are no discussions about vaccine evaluations in Africa. And yet suddenly, we have all these advanced programmes for chikungunya and the chikungunya pipeline is very healthy, but none of those products actually have a strategy for evaluation in Africa, as far as I am aware.... This promotes inequity.”

308

-Vaccinologist and One Health expert, Kenya

309

310

Because of prioritisation of other diseases, the community engagement process to raise awareness about chikungunya is lacking. This concern is emphasised by African stakeholders, where the lack of

311 awareness about the disease poses challenges for future interventions and highlights evidence gaps
312 associated with perception of the disease and stigma.

313

314 *“Chikungunya is known, but it is stereotyped as a disease that came from spirits*
315 *from the ocean, or is linked to witchcraft, they think that a treatment is drinking*
316 *boiled papaya leaves. People know this thing (CHIKV) exists, but general*
317 *knowledge about chikungunya is lacking. Most people know about malaria, what*
318 *symptoms are, they know about malaria treatment, but if you talk about*
319 *chikungunya they laugh at you because public engagement has not been done for*
320 *chikungunya.”*

321

-Academic researcher, Kenya

322

323 Target population for the chikungunya vaccine is not well defined

324 The target population for a vaccine includes individuals within defined demographics and
325 geographies that are eligible for a vaccine intervention. The unknown target population for the
326 chikungunya vaccine presents challenges to all tiers of stakeholders. For global stakeholders, the
327 biggest implication for unknown target population is the impact this has on industry manufacturing.

328

329 *“Things have already been done and spearheaded by individual vaccine*
330 *manufacturers to push the [CHIKV vaccine] development path forward. The*
331 *biggest impediment for chikungunya vaccine development has not been technical,*
332 *but defining what the market is for a chikungunya vaccine. There is not a huge*
333 *amount of public funding for chikungunya vaccine development because of*
334 *morbidity and mortality and burden issues. The commercial market is limited. Big*
335 *players are not vaccine multinationals, but more intermediate developers, or ones*
336 *located in endemic countries... the biggest impediment has been what is the*
337 *commercial market that makes it worth developing?”*

338

-Programme lead for chikungunya, international organisation

339

340 For national and subnational stakeholders, the undefined target population presents more concerns
341 for vaccine roll-out logistics in their countries.

342

343 *“What we see in the Paraguay outbreak is that more children have been infected*
344 *and there have been more fatalities in children, so we need more information on*
345 *this. The diagnostics and surveillance previously available have been weak to*
346 *detect the type of infection some of these children have... Maybe children were*
347 *not affected so much in previous outbreaks, but going forward we need to be*
348 *aware of child infections. For example, from which age should we vaccinate?”*

349

-Physician and clinical researcher, Colombia

350

351 Additionally, concerns around vaccine hesitancy and vaccine equity highlight the need for
352 identification of target populations ahead of vaccine roll-out and ensuring that vaccine roll-out is
353 packaged alongside advocacy campaigns.

354

355 *“Some important questions that need to be addressed soon, include: if vaccine*
356 *supplies are limited, which population groups are considered priority groups? The*
357 *purpose of vaccination is to achieve what objective? To ensure equity in vaccine*
358 *distribution, what steps do we need to take?”*

359

-Neglected tropical diseases division, national organisation, Brazil

360

361 Climate sensitivity of Chikungunya vectors

362 Sub-populations experience different disease burdens because of differences in exposure to
363 mosquito bites. Stakeholders explain that variations in vector exposure is an important consideration
364 in vaccine roll-out because certain populations are disproportionately affected. As climate change
365 impacts vector and virus population dynamics, CHIKV may become endemic in some countries, this
366 has implications for vaccine stockpiles and roll-out.

367

368 *“In Guatemala, we have a lot of areas of high rain, humidity and areas for*
369 *mosquitoes to grow. Alongside, our population is growing, and we have a large*
370 *urban population, so more people in small places, which makes the perfect*
371 *conditions for an outbreak.”*

372

-Paediatric infectious disease specialist, Guatemala

373

374 *“Africa is the only continent that has reported sylvatic circulation, between*
375 *primates and mosquitoes. This is the natural reservoir for CHIKV, so we need to do*
376 *a thorough study of chikungunya in Africa because even if the vaccine is rolled out*
377 *elsewhere and people are protected, we don’t know what strains will come again*
378 *from the natural habitat for the virus, especially as climate changes the evolution*
379 *of viruses. So, these viruses, as much as you can control them elsewhere, these*
380 *viruses will again spread from their original source. So, to address challenges for*
381 *chikungunya, it is better to address them from the source.”*

382

-Academic researcher, Kenya

383

384 Existing evidence gaps

385 Regional stakeholder perspectives were aligned with EtR criteria to highlight existing gaps in
386 knowledge. Where stakeholders believed an EtR criterion was a current challenge or a gap in
387 knowledge, it was recorded in Table 3. If no annotation was made for any of the criterion, this means
388 the topic was not discussed during the stakeholder interviews or the topic was not identified as a
389 current evidence gap.

390 **Table 3. Mapping stakeholder perspectives with Evidence to Recommendation (EtR) criteria.** Stakeholder perspectives were aligned with Evidence to
 391 Recommendation criteria to highlight existing gaps in knowledge. The red crosses indicate the number of stakeholders who identified each criterion as a
 392 knowledge gap or challenge.

Evidence to Recommendation Criteria		Stakeholders identifying a specific criterion as a knowledge gap or challenge			
		Africa (n=2)	Asia (n=4)	Latin America (n=9)	International (n=3)
1. Framing the problem	Burden of disease	++	++++	+++++++	++
	Clinical characteristics	++		++++	
2. Benefits and harms of vaccination	Vaccine efficacy and safety	++	+++	+	+
	Indirect effects of vaccination	+			
3. Values and preferences of target population	Well-defined target population	++	+++	+++++	++
	Perception of the disease	+	++	++++	+
	Perception of vaccination	+	+++	+++++++	
	Differences in subgroups	++	++	+++++++	+
4. Acceptability of the vaccine	Financial & ethical considerations	++	+	+++	
	Economic impact of vaccination	+	++	+	+++
5. Resources	Socioeconomic factors			++++	
	Diagnostics and laboratory capacities	++	++	++++	+
6. Vaccine equity	Access to vaccination	+		+++++++	
	Stigma	+			
7. Feasibility	Storage and distribution	+	++	+++++++	++

	Vaccine availability	†	†	†	
	Information management	††	††	††††††	†
	Disease surveillance	††	††	††††	†

394 Discussion

395 We infer from our stakeholder analysis that unknown disease burden, diagnostics, non-specific
396 disease surveillance, undefined target populations for vaccination, and low disease prioritisation are
397 critical challenges that need to be addressed to facilitate rolling out a chikungunya vaccine. Future
398 investments should address these challenges to generate useful evidence for decision-making on
399 new chikungunya vaccine introduction.

400
401 Both disease burden and surveillance were highlighted as gaps in the Evidence to Recommendation
402 criteria across all geographical regions, further stressing these as major issues that need addressing
403 ahead of vaccine rollout. Paucity of data and research illustrating the disease burden of chikungunya,
404 exacerbated by non-specific disease surveillance presents several challenges. The disease burden of
405 chikungunya remains unknown and likely under-estimated in many high burden settings due to a lack
406 of chikungunya-specific disease surveillance [20]. Laboratory capacity and existing diagnostics for
407 detecting chikungunya infection are limited in some high burden settings [21]. Passive surveillance
408 methods currently used in many settings only pick up clinical cases of chikungunya presenting to
409 hospital, resulting in an under diagnosis of asymptomatic and less severe infections. Analysis of age-
410 stratified seroprevalence data is a useful method for estimating long-term average infection burden.
411 In some African settings, misdiagnosis of chikungunya as another febrile illness, such as malaria, is
412 common, which is concerning, given that research shows a higher burden of chikungunya in children
413 [22]. Accurate detection and surveillance of alphaviruses in vectors is especially important in Africa
414 (and other malaria endemic areas) where existing zoonotic reservoirs exist and there has been an
415 increasing frequency of chikungunya detection in recent years [23]. Accordingly, stakeholders in
416 Africa highlighted the indirect effects of vaccination as a current evidence gap that would be valuable
417 to address alongside cross-protections from chikungunya and other viruses.

418
419 The unknown disease burden also affects prioritisation of chikungunya, both in terms of national
420 vaccine policy decisions [20] and public perception of chikungunya risk [16]. Several stakeholders
421 highlighted that by focusing on chikungunya vaccination, resources are taken away from dengue
422 vaccination and prevention, which many stakeholders, especially those in South and Southeast Asia,
423 believe is a higher priority on country agendas. In contrast, stakeholders in Latin America affirmed a
424 higher prioritisation of chikungunya in national vaccine policy agendas, but voiced concerns that
425 public perception of chikungunya risk was skewed by a greater awareness about dengue, including
426 symptoms, transmission and infection risk. Because chikungunya is often seen as a disease with low
427 mortality, stakeholders voiced concerns in the public perception of risk [16, 24]. Lower prioritisation
428 of chikungunya is concerning because the long-term chronic side effects of chikungunya fever can be
429 debilitating, putting stress on health care systems and diminishing economic productivity. These
430 health deficits for chikungunya are not usually captured in global health assessments despite the
431 large populations currently at risk [25]. By illustrating the true burden of chikungunya and long-term
432 consequences associated with the disease, stakeholders were confident that prioritisation and public
433 perception of chikungunya risk can be increased.

434
435 Concern for social factors affecting vaccine rollout were varied across geographical regions.
436 Stakeholders in Africa and Latin America identified vaccine perception and hesitancy, information
437 management and socioeconomic factors affecting vaccine uptake as current challenges more often
438 than stakeholders in Asia. This could be attributed to the overall perception and prioritisation of
439 chikungunya—stakeholders in Latin America saw chikungunya as a higher priority disease whilst
440 stakeholders in Asia stated other disease with competing interests were a higher priority. This
441 differential prioritisation could affect concern for social factors around vaccination, showing a greater
442 level of thought has been put into chikungunya vaccine equity amongst stakeholders that see the
443 vaccine as more favourable. Stakeholders discussed synergies with other vaccination programmes,

444 specifically citing lessons learned from distribution and administration of COVID-19 vaccines.
445 Stakeholders in Latin America and Asia believed lessons learned during the COVID-19 pandemic
446 could be leveraged for the chikungunya vaccine, however, stakeholders in Africa saw the ongoing
447 inequity of COVID-19 vaccines in Africa to perpetuate concerns about chikungunya vaccine equity in
448 the African continent.

449

450 New chikungunya vaccines provide broader value beyond the direct benefits of lowering the
451 chikungunya disease burden. These will be the first-ever vaccines against an alphavirus and thereby
452 offer new platforms for vaccine development against other alphaviruses of the *Togaviridae* family
453 that may emerge to cause epidemics and potential for pandemics. Further, the lessons learned, and
454 technologies developed by the chikungunya vaccine will pave the way for new regulatory approval
455 processes as vaccines can be approved based on vaccine efficacy estimated by measures of
456 neutralizing antibodies as a potential immune correlate of protection, instead of disease events [26].

457

458 Our study has limitations. By limiting our analysis to stakeholders in regions at risk of chikungunya
459 outbreaks, stakeholders in regions at future risk of chikungunya invasion due to climate change were
460 excluded from our interview sample. We used a limited number of organisational databases that not
461 all relevant stakeholders were identified. Despite contacting over 60 stakeholders, the response rate
462 was low. When stakeholders were referred by other stakeholders, they were more likely to
463 participate, suggesting that use of purposive sampling in addition to the low response rate could
464 result in selection bias. The sample of interviewees is geographically representative of current
465 willingness to roll-out the chikungunya vaccine, but the number of participants by region is not
466 necessarily proportional to disease burden. For example, Latin America had the greatest number of
467 participants across all geographies and it was also the region with the most eagerness to rollout the
468 vaccine; however, the burden of disease in Africa is estimated to be relatively high, especially in
469 children [22], and this burden was not proportional to the sample size of stakeholders from the
470 African region included in our study. This limited sample size for Africa could be attributed to topics
471 mentioned in interviews with stakeholders who expressed concern that chikungunya epidemiology is
472 not currently well documented and disease awareness is low across the African region. Despite the
473 low sample size, we were still able to interview stakeholders from four different high burden
474 geographical regions, six different countries, and across the international, national and subnational
475 organisation tiers, lending to diverse perspectives that will be valuable in making future decisions
476 about chikungunya vaccination.

477

478 Especially given shifts in global travel patterns, urbanisation and climate change, as vector viability
479 changes, public health officials must collaborate to improve surveillance, prevention, and control
480 programmes for arboviral diseases [27-29]. In July 2023, the European Centre for Disease Prevention
481 and Control (ECDC) announced an increasing risk of mosquito-borne disease in Europe following the
482 spread of *Aedes* mosquito species capable of transmitting CHIKV [30]. While our analysis focused on
483 perspectives in regions at current risk of chikungunya outbreaks and excluded Europe, the rising
484 concern of transmission-competent mosquito populations in Europe highlights just one aspect of
485 how changing climate patterns can shift the future epidemiology of chikungunya outbreaks. To
486 address these evolving patterns, the involvement of stakeholders in all phases of vaccine
487 development and rollout alongside risk assessment and climate sensitivity of chikungunya will be
488 crucial to uncover challenges and gaps to be addressed in the future.

489 **Authors' contributions**

490 MA, CM, SS, and KA conceptualised the study. MA synthesised the interview topics, developed the
491 interview questionnaire, conducted the stakeholder interviews, curated and analysed the qualitative
492 data, and wrote the original draft. MA and CM independently validated the data and themes
493 identified. All authors contributed to interpretation of results, critical review and editing of the
494 manuscript, and have approved the final version. The authors alone are responsible for the views
495 expressed in this article and they do not necessarily represent the decisions, policy or views of their
496 affiliated organisations nor the organisations of the stakeholders included in this study.

497

498 **Acknowledgements**

499 This project was funded by the International Vaccine Institute. HK is supported by the Vaccine Impact
500 Modelling Consortium. OJB was supported by a UK Medical Research Council Career Development
501 Award (MR/V031112/1). KA is supported by the Vaccine Impact Modelling Consortium (INV-034281)
502 and the Japan Agency for Medical Research and Development (JP223fa627004). We would like to
503 thank Asha Mary Abraham, Ashish Bavdekar, Doris Nyamwaya, Eolo Morandi Jr, Jacqueline Borin,
504 Jammille Dombrowski, José Moreira, Elsa Marina Rojas Garrido, Maria Isabel Estupiñan Cárdenas,
505 Mario Melgar, Myriam Tatiana Medina Bernal and Timothy Endy for their valuable insights and
506 perspectives shared during the interviews.

507

508 **Declaration of interests**

509 The authors have no conflicts of interest to declare.

510

511 **Data sharing**

512 Stakeholders consented to interviews understanding that the data collected would not be shared
513 publicly nor include names and organisations' names. The data used in this analysis will be shared
514 anonymously upon reasonable request.

515 References

- 516 1. Calabrese LH. Emerging viral infections and arthritis: the role of the rheumatologist. *Nature*
517 *clinical practice Rheumatology*. 2008;4(1):2-3.
- 518 2. Dupuis-Maguiraga L, Noret M, Brun S, Le Grand R, Gras G, Roques P. Chikungunya disease:
519 infection-associated markers from the acute to the chronic phase of arbovirus-induced arthralgia.
520 *PLoS neglected tropical diseases*. 2012;6(3):e1446.
- 521 3. Burt F, Chen W, Mahalingam S. Chikungunya virus and arthritic disease. *The Lancet Infectious*
522 *Diseases*. 2014;14(9):789-90.
- 523 4. Bartholomeeusen K, Daniel M, LaBeaud DA, Gasque P, Peeling RW, Stephenson KE, et al.
524 Chikungunya fever. *Nature Reviews Disease Primers*. 2023;9(1):17.
- 525 5. Laporta GZ, Potter AM, Oliveira JF, Bourke BP, Pecor DB, Linton Y-M. Global distribution of
526 *Aedes aegypti* and *Aedes albopictus* in a climate change scenario of regional rivalry. *Insects*.
527 2023;14(1):49.
- 528 6. Mourad O, Makhani L, Chen LH. Chikungunya: An Emerging Public Health Concern. *Curr*
529 *Infect Dis Rep*. 2022;24(12):217-28. Epub 2022/11/24. doi: 10.1007/s11908-022-00789-y. PubMed
530 PMID: 36415286; PubMed Central PMCID: PMCPCMC9672624.
- 531 7. Wressnigg N, Hochreiter R, Zoihsel O, Fritzer A, Bézay N, Klingler A, et al. Single-shot live-
532 attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial. *The Lancet*
533 *Infectious Diseases*. 2020;20(10):1193-203.
- 534 8. Valneva. Chikungunya – VLA1553 [30 May 2023]. Available from:
535 <https://valneva.com/research-development/chikungunya/>.
- 536 9. GAVI. Vaccine Investment Strategy 2024. Available from: [https://www.gavi.org/our-](https://www.gavi.org/our-alliance/strategy/vaccine-investment-strategy-2024#introduction)
537 [alliance/strategy/vaccine-investment-strategy-2024#introduction](https://www.gavi.org/our-alliance/strategy/vaccine-investment-strategy-2024#introduction).
- 538 10. Cherian N, Bettis A, Deol A, Kumar A, Di Fabio JL, Chaudhari A, et al. Strategic considerations
539 on developing a CHIKV vaccine and ensuring equitable access for countries in need. *npj Vaccines*.
540 2023;8(1):123. doi: 10.1038/s41541-023-00722-x.
- 541 11. Lundstrom K. Alphavirus-based vaccines. *Viruses*. 2014;6(6):2392-415. Epub 2014/06/18.
542 doi: 10.3390/v6062392. PubMed PMID: 24937089; PubMed Central PMCID: PMCPCMC4074933.
- 543 12. Excler J-L, Saville M, Berkley S, Kim JH. Vaccine development for emerging infectious
544 diseases. *Nature Medicine*. 2021;27(4):591-600. doi: 10.1038/s41591-021-01301-0.
- 545 13. World Health Organization. Guidance on an adapted evidence to recommendation process
546 for National Immunization Technical Advisory Groups. World Health Organization. Regional Office for
547 Europe, 2022.
- 548 14. Rezza G. Do we need a vaccine against chikungunya? *Pathogens and Global Health*.
549 2015;109(4):170-3. doi: 10.1179/2047773215Y0000000017.
- 550 15. Elsinga J, Grobusch MP, Tami A, Gerstenbluth I, Bailey A. Health-related impact on quality of
551 life and coping strategies for chikungunya: A qualitative study in Curaçao. *PLoS Neglected Tropical*
552 *Diseases*. 2017;11(10):e0005987.
- 553 16. Corrin T, Waddell L, Greig J, Young I, Hierlihy C, Mascarenhas M. Risk perceptions, attitudes,
554 and knowledge of chikungunya among the public and health professionals: a systematic review.
555 *Tropical medicine and health*. 2017;45:1-15.
- 556 17. MacQueen KM, McLellan E, Kay K, Milstein B. Codebook development for team-based
557 qualitative analysis. *Cam Journal*. 1998;10(2):31-6.
- 558 18. Burdino E, Calleri G, Caramello P, Ghisetti V. Unmet Needs for a Rapid Diagnosis of
559 Chikungunya Virus Infection. *Emerg Infect Dis*. 2016;22(10):1837-9. Epub 2016/06/28. doi:
560 10.3201/eid2210.151784. PubMed PMID: 27347706; PubMed Central PMCID: PMCPCMC5038423.
- 561 19. Natrajan MS, Rojas A, Waggoner JJ. Beyond Fever and Pain: Diagnostic Methods for
562 Chikungunya Virus. *J Clin Microbiol*. 2019;57(6). Epub 2019/04/19. doi: 10.1128/jcm.00350-19.
563 PubMed PMID: 30995993; PubMed Central PMCID: PMCPCMC6535601.

- 564 20. Puntasecca CJ, King CH, LaBeaud AD. Measuring the global burden of chikungunya and Zika
565 viruses: A systematic review. *PLoS neglected tropical diseases*. 2021;15(3):e0009055.
- 566 21. Moreira J, Fernandez-Carballo BL, Escadafal C, Dittrich S, Brasil P, de Siqueira AM. Addressing
567 Acute Febrile Illness Using a Syndromic Approach During A Chikungunya Epidemic in Rio de Janeiro,
568 Brazil: A Prospective Observational Study. *medRxiv*. 2023:2023.04. 15.23288370.
- 569 22. Nyamwaya DK, Otiende M, Omuoyo DO, Githinji G, Karanja HK, Gitonga JN, et al. Endemic
570 chikungunya fever in Kenyan children: a prospective cohort study. *BMC Infectious Diseases*.
571 2021;21(1):186. doi: 10.1186/s12879-021-05875-5.
- 572 23. Sang RC, Dunster L. The growing threat of arbovirus transmission and outbreaks in Kenya: a
573 review. *East African medical journal*. 2001;78(12):655-61.
- 574 24. Fritzell C, Raude J, Adde A, Dusfour I, Quenel P, Flamand C. Knowledge, attitude and practices
575 of vector-borne disease prevention during the emergence of a new arbovirus: implications for the
576 control of chikungunya virus in French Guiana. *PLoS Neglected Tropical Diseases*.
577 2016;10(11):e0005081.
- 578 25. LaBeaud A, Bashir F, King CH. Measuring the burden of arboviral diseases: the spectrum of
579 morbidity and mortality from four prevalent infections. *Population Health Metrics*. 2011;9(1):1. doi:
580 10.1186/1478-7954-9-1.
- 581 26. Finch CL, Martinez C, Leffel E, Skiadopoulou MH, Hacker A, Mwesigwa B, et al. Vaccine
582 licensure in the absence of human efficacy data. *Vaccines*. 2022;10(3):368.
- 583 27. Gubler DJ. The Global Emergence/Resurgence of Arboviral Diseases As Public Health
584 Problems. *Archives of Medical Research*. 2002;33(4):330-42. doi: [https://doi.org/10.1016/S0188-4409\(02\)00378-8](https://doi.org/10.1016/S0188-4409(02)00378-8).
- 585
586 28. Longbottom J, Walekhwa AW, Mwingira V, Kijanga O, Mramba F, Lord JS. *Aedes albopictus*
587 invasion across Africa: the time is now for cross-country collaboration and control. *The Lancet Global*
588 *Health*. 2023;11(4):e623-e8.
- 589 29. Love E, Walker, D. The Road to a Chikungunya Vaccine: Accelerating Solutions to Addressing
590 Health Threats Posed by Climate Change Management Sciences for Health2023 [cited 2023 25
591 September]. Available from: [https://msh.org/story/the-road-to-a-chikungunya-vaccine-accelerating-](https://msh.org/story/the-road-to-a-chikungunya-vaccine-accelerating-solutions-to-addressing-health-threats-posed-by-climate-change/)
592 [solutions-to-addressing-health-threats-posed-by-climate-change/](https://msh.org/story/the-road-to-a-chikungunya-vaccine-accelerating-solutions-to-addressing-health-threats-posed-by-climate-change/).
- 593 30. European Centre for Disease Prevention and Control. Increasing risk of mosquito-borne
594 diseases in EU/EEA following spread of *Aedes* species 2023 [3 July 2023]. Available from:
595 [https://www.ecdc.europa.eu/en/news-events/increasing-risk-mosquito-borne-diseases-eueea-](https://www.ecdc.europa.eu/en/news-events/increasing-risk-mosquito-borne-diseases-eueea-following-spread-aedes-species#:~:text=of%20Aedes%20species-.Increasing%20risk%20of%20mosquito%2Dborne%20diseases%20in%20EU%2FEEA,following%20spread%20of%20Aedes%20species&text=The%20mosquito%20species%20Aedes%20albopictus,the%20latest%20data%20from%20ECDC)
596 [following-spread-aedes-species#:~:text=of%20Aedes%20species-](https://www.ecdc.europa.eu/en/news-events/increasing-risk-mosquito-borne-diseases-eueea-following-spread-aedes-species#:~:text=of%20Aedes%20species-.Increasing%20risk%20of%20mosquito%2Dborne%20diseases%20in%20EU%2FEEA,following%20spread%20of%20Aedes%20species&text=The%20mosquito%20species%20Aedes%20albopictus,the%20latest%20data%20from%20ECDC)
597 [.Increasing%20risk%20of%20mosquito%2Dborne%20diseases%20in%20EU%2FEEA,following%20spr](https://www.ecdc.europa.eu/en/news-events/increasing-risk-mosquito-borne-diseases-eueea-following-spread-aedes-species#:~:text=of%20Aedes%20species-.Increasing%20risk%20of%20mosquito%2Dborne%20diseases%20in%20EU%2FEEA,following%20spread%20of%20Aedes%20species&text=The%20mosquito%20species%20Aedes%20albopictus,the%20latest%20data%20from%20ECDC)
598 [ead%20of%20Aedes%20species&text=The%20mosquito%20species%20Aedes%20albopictus,the%20](https://www.ecdc.europa.eu/en/news-events/increasing-risk-mosquito-borne-diseases-eueea-following-spread-aedes-species#:~:text=of%20Aedes%20species-.Increasing%20risk%20of%20mosquito%2Dborne%20diseases%20in%20EU%2FEEA,following%20spread%20of%20Aedes%20species&text=The%20mosquito%20species%20Aedes%20albopictus,the%20latest%20data%20from%20ECDC)
599 [latest%20data%20from%20ECDC](https://www.ecdc.europa.eu/en/news-events/increasing-risk-mosquito-borne-diseases-eueea-following-spread-aedes-species#:~:text=of%20Aedes%20species-.Increasing%20risk%20of%20mosquito%2Dborne%20diseases%20in%20EU%2FEEA,following%20spread%20of%20Aedes%20species&text=The%20mosquito%20species%20Aedes%20albopictus,the%20latest%20data%20from%20ECDC).
- 600

Clinical development

Phase 1:

- HBI/CG/1/2020/001.02.00, Human Biologicals Institute, India
- ChAdOx1 Chik, University of Oxford

Phase 2:

- MV-CHIK, Themis Bioscience

Phase 3:

- VLA 1553, Valneva SE
- BBV87, BBIL/IVI
- PXVX0317, Bavarian Nordic

NRA + WHO policy guidelines

+

Licensure & marketing authorization

- Pre-qualification eligibility requirements
- Invitation for vaccine priority list
- Potential joint review, data sharing and coordination

Regulatory approval & registration by NRAs

SAGE recommendation

**WHO
PQ**

MoH / EPI interest

NITAG recommendations

Launch of global financing and procurement mechanisms

In country distribution

FRAMING THE PROBLEM

1

- Burden of disease
- Clinical characteristics
- Regional differences

BENEFITS & HARMS OF VACCINATION

2

- Efficacy and safety
- Indirect effects

VALUES & PREFERENCES OF TARGET POPULATION

3

- Well-defined target population
- Perception of the disease
- Perception of vaccination
- Subgroup differences

ACCEPTABILITY TO STAKEHOLDERS

4

- Acceptability of vaccination
- Financial and ethical considerations

RESOURCES

5

- Economic impact of vaccination
- Socioeconomic factors

VACCINE EQUITY

6

- Access to vaccination
- Stigma

FEASIBILITY

7

- Storage and distribution of vaccines
- Vaccine availability
- Information management
- Disease surveillance